Press Releases Details

Paras Biopharmaceuticals Announces Successful Client Audit as Critical Supplier for Recombinant Biologics (Bulk) – Ancillary Materials

Oulu, Finland 3rd July 2024: – PARAS BIOPHARMACEUTICALS FINLAND is pleased to announce successful review & site Audit (Finland facility) by Paras European CDMO client. CDMO client reviewed Paras Biopharmaceuticals’ manufacturing set up as critical supplier of recombinant biologics (Bulk Production) – Ancillary Materials. Paras Biopharma team is happy to see that Audit proceeded well. Paras Biopharmaceuticals is carrying out scale-up manufacturing for European & USA clients for optimisation of bulk for non-human applications.

About Paras Biopharmaceuticals Finland Oy: Paras Biopharmaceuticals’ major activities are “Biologics CDMO” Services and Biologics & Biosimilar Technology Development & Scale-up, in addition to offering co-development & licensing partnership opportunities of high-value Biologics. Paras Biopharma’s unique technologies (Biomultifold®, Noblecleav® and Cytofold StructQuant®) facilitates achieving high productivity & quality of biologics.

Paras Biopharmaceuticals has established its expertise in critical areas providing biologics CDMO, development of complex proteins from early stage to large scale, and the development of enzymes for medicinal and bioprocess purposes.

Paras Biopharmaceuticals has a fully equipped biologics production facility in Finland for the manufacturing of recombinant therapeutic products in microbial systems. The state-of-art biologics production plant includes a total floor area of 25,000 ft² and a classified cleanroom of 4,300 ft². Other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying. Paras Biopharmaceuticals has a Biologics CDMO Services pipeline www.parasbiopharma.com/microbial-biologics-cdmo.php and Biosimilars in Onco-Immunology, Urology, Osteoporosis and Rheumatoid Arthritis.

For further information, please contact:
Media Relations & Information
Dr. Mark Jackson
Tel: +358 442709462 / Email: mark.jackson@parasbiopharma.com